OncLive TV

Herbert A. Eradat, MD, associate professor, University of California, Los Angeles Medical Center, discusses unmet needs in chronic lymphocytic leukemia.

Camille C. Gunderson, MD, discusses the phase III open-label GOG-252 trial in advanced ovarian cancer.

Eric Jonasch, MD, on how understanding features within the tumor microenvironment and mutated epigenetic modifying genes may provide insight on prognosis or treatment strategies in renal cell carcinoma.

Manfred Welslau, MD, Internal Medicine, Hematology and Oncology, Onkologie Aschaffenburg, discusses the rationale for the REFLECT trial in diffuse large B-cell lymphoma.

Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses ongoing challenges in the management of patients with metastatic HER2-positive breast cancer.

Kathleen Moore, MD, director, Oklahoma TSET Phase I Program, and associate professor, Section of Gynecologic Oncology, Stephenson Cancer Center, discusses research evaluating repeat exposure to PARP inhibition in patients with platinum-sensitive ovarian cancer.

Emil Israel Cohen, MD, an assistant professor at Medstar Georgetown University Hospital, discusses the criteria for ablation therapy in patients with liver cancer.

Paul D. Nathan, MBBS, PhD, FRCP, consultant medical oncologist, Mount Vernon Cancer Centre, discusses the long-term outcomes with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF V600-mutant unresectable or metastatic melanoma.

Donald A. Richards, MD, PhD, medical oncologist, Texas Oncology, discusses PARP inhibition in patients with pancreatic cancer.

Manish R. Patel, DO, discusses choosing immunotherapy drugs for patients with non–small cell lung cancer.

Gary H. Lyman, MD, MPH, senior lead, Health Care Quality and Policy, Hutchinson Institute for Cancer Outcomes Research, member, Cancer Prevention Program, Public Health Services Division, and member, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the use of rituximab (Rituxan) biosimilars in the treatment of patients with non-Hodgkin lymphoma (NHL).

Elizabeth Petri Henske, MD, director of the Center for LAM Research and Clinical Care, co-director of the Pulmonary Genetics Center at Brigham and Women’s Hospital, and professor at Harvard Medical School, discusses a newly discovered pathway in chromophobe renal cell carcinoma.

Daniel J. George, MD, professor of medicine and surgery, member, Duke Cancer Institute, discusses the use of radium-223 dichloride (Xofigo) in prostate cancer.

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses anticipated research in mantle cell lymphoma (MCL).

Christopher S. Seet, MD, PhD, hematologist and oncologist, UCLA, discusses aspects of treatment discontinuation in chronic myeloid leukemia (CML).

Petros Grivas, MD, discusses searching for biomarkers in patients with urothelial cancer to indicate response to pembrolizumab in the KEYNOTE-052 trial.

Gulam A. Manji, MD, PhD, discusses treatment for patients with colorectal cancer who harbor NTRK fusions.

Bianca D. Santomasso, MD, PhD, discusses how she prevents central nervous system toxicity due to CAR T-cell therapy for aggressive B-cell lymphoma in her own practice.

Simon Rule, MD, discusses a study comparing patients with newly diagnosed mantle cell lymphoma who receive immediate systemic treatment immediately versus patients who are closely monitored instead.

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses how to choose between combination treatments in advanced renal cell carcinoma.

Hans Hammers, MD, PhD, associate professor of internal medicine, Division of Hematology-Oncology, UT Southwestern Medical Center, discusses the challenges with using CAR T-cell therapy in renal cell carcinoma.

Inga T. Lennes, MD, MBA, MPH, senior vice president of Performance Improvement and Service Excellence of the Mass General Physicians Organization, medical director, Ambulatory Services, and director of clinical quality, Massachusetts General Hospital Cancer Center, discusses ongoing research on screening techniques for lung cancer.

Peter Schmid, MD, PhD, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, discusses the evaluation of biosimilars in oncology.

Justin F. Gainor, MD, director of Targeted Immunotherapy, Massachusetts General Hospital, and assistant professor of medicine, Harvard Medical School, discusses neoadjuvant checkpoint blockade in non–small cell lung cancer (NSCLC).

Joshua P. Sasine, MD, PhD, clinical instructor of medicine, hematologist, and oncologist, University of California, Los Angeles, discusses new developments with CAR T-cell therapy.

Andrea De Censi, MD, director of the medical oncology unit at the National Hospital E.O. Ospedali Galliera–SC Oncologia Medica in Genoa, Italy, discusses the hope for biosimilars in the United States.

Tanya Siddiqi, MD, a hematologist/oncologist at City of Hope, discusses the safety profile of lisocabtagene maraleucel (liso-cel; JCAR017) in the TRANSCEND CLL 004 trial.

Neelima Denduluri, MD, medical oncologist, Virginia Cancer Specialists, discusses the role of neoadjuvant therapy in HER2-positive breast cancer and triple-negative breast cancer.

Peter Voorhees, MD, physician, Levine Cancer Institute, Atrium Health, discusses the randomized phase II ELOQUENT-3 trial in relapsed/refractory multiple myeloma.

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses where future research should focus in metastatic colorectal cancer.